The merger of Kraft with Heinz once looked like a Big Food success story. But the industry is changing, @AChilkoti tells “The Intelligence”, and now a split seems likely https://t.co/RwAghBJAq1 ...

Synovus Financial, regional bank in the southeastern US, is weighing options including a potential merger after drawing interest https://t.co/nZ9X2LZ6K0 ...

Seven & i pushed back on Couche-Tard’s claims it avoided merger talks, saying the Canadian firm downplayed antitrust risks and misunderstood Japan’s business culture https://t.co/ALhcZVgCO3 ...

Merger Announcement - UpTop 项目已与纳斯达克上市公司 BIYA 签署战略合并框架协议 [1] - 美东时间上午 9 点，BIYA (NASDAQ: BIYA) 宣布与 UPTOP 项目签署战略合并协议 [1] Industry Impact - 该合并框架协议标志着 BNB Chain 项目与华尔街的潜在融合 [1]

RT UpTop.meme (@uptopmeme)Official Announcement: UPTOP has officially signed a strategic merger framework agreement with NASDAQ listed company BIYA!At 9:00 AM New York time, U.S. listed company BIYA (NASDAQ: BIYA) released news declaring the signing of a strategic merger agreement with UPTOP project owner STARFISH TECHNOLOGY-FZE, headquartered in Dubai. This marks an important milestone in our journey to realize the vision of becoming the “world’s largest decentralized liquidity infrastructure.”BIYA’s news ...

Core Points - Ikena Oncology, Inc. announced the results of its annual stockholder meeting, where stockholders approved the merger with Inmagene Biopharmaceuticals [2][3] - The combined company will be named ImageneBio, Inc. and will trade on Nasdaq under the ticker symbol "IMA" [3] - A 1-for-12 reverse stock split will be executed, reducing the number of outstanding shares from approximately 48.2 million to about 4 million [3][4] Company Overview - Ikena Oncology focuses on developing differentiated therapies targeting cancer growth, spread, and therapeutic resistance [6] - Inmagene Biopharmaceuticals is a clinical-stage biotechnology company developing therapeutics for immunological and inflammatory diseases, with its lead asset IMG-007 recently completing Phase 2a trials [5][6] Merger Details - The merger allows for the issuance of shares of Ikena's common stock to Inmagene shareholders and investors involved in the financing concurrent to the merger [3] - The reverse stock split is expected to be effective around the end of July, prior to the merger closing [3][4] - The new CUSIP number for the combined company's common stock will be 45175G 207 [3] Product Information - IMG-007 is a humanized, subcutaneously administered monoclonal antibody targeting OX40, showing promising results in clinical trials for atopic dermatitis and alopecia areata [7] - The drug demonstrated a half-life of 34.7 days, supporting infrequent dosing [7] - In clinical trials, IMG-007 exhibited sustained clinical activity and was well tolerated, with no significant adverse effects reported [7]

Core Viewpoint - Portman Ridge Finance Corporation (PTMN) has successfully completed its merger with Logan Ridge Finance Corporation (LRFC), resulting in a combined entity with total assets exceeding $600 million as of July 11, 2025 [1][3]. Company Overview - PTMN will be rebranded as BCP Investment Corporation later in the summer of 2025 to reflect its affiliation with the BC Partners Credit Platform [2][7]. - The company operates as a publicly traded, externally managed closed-end investment company regulated under the Investment Company Act of 1940, focusing on middle market investments [9]. Financial Details - LRFC shareholders will receive approximately 4.0 million shares of PTMN common stock, equating to 1.5 shares of PTMN for each LRFC share, along with cash payments for fractional shares [3]. - Prior to the merger, LRFC announced a cash payment of $0.47 per share to its shareholders, with an additional tax distribution of $0.38 per share declared on July 14, 2025 [4]. Future Initiatives - Starting in 2026, the company plans to transition to monthly base distributions while maintaining the potential for quarterly supplemental distributions, which will approximate 50% of incremental net investment income [7]. - Over the next 24 months, the company intends to repurchase up to 20% of its outstanding common stock if shares trade below 80% of net asset value (NAV), with a share price target of $15.08 based on March 31, 2025 NAV [7]. Advisory and Legal Support - Keefe, Bruyette & Woods served as the financial advisor to PTMN's Special Committee, while Houlihan Lokey acted as the financial advisor to LRFC's Special Committee [6][8].

Core Points - FARO Technologies, Inc. has announced that its shareholders approved the acquisition by AMETEK, Inc. at a Special Meeting [1][2] - Over 99% of votes cast were in favor of the merger agreement, which required a majority vote from FARO's outstanding shares [2] - Upon completion of the merger, FARO shareholders will receive $44 in cash for each share of FARO common stock, with the transaction expected to close in the second half of 2025, pending regulatory approvals [3] Company Information - FARO has been a leader in technology solutions for over 40 years, focusing on enabling customers to measure their world and make informed decisions [5] - The company is recognized for its innovative approach in bridging digital and physical realities through reliable data accuracy and immediacy [5] Advisory Information - Evercore is serving as the exclusive financial advisor, while Foley & Lardner LLP is acting as the legal advisor to FARO during this merger process [4]

Core Viewpoint - Ikena Oncology, Inc. has received recommendations from Institutional Shareholder Services Inc. and Glass, Lewis & Co. to vote in favor of the share issuance related to the proposed merger with Inmagene Biopharmaceuticals at the upcoming Annual Meeting of Stockholders on July 15, 2025 [1][2]. Company Overview - Ikena Oncology focuses on developing differentiated therapies targeting cancer growth, spread, and therapeutic resistance [6]. - Inmagene Biopharmaceuticals is a clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases, with its lead asset IMG-007 recently completing a Phase 2a clinical trial in atopic dermatitis [5][6]. Product Details - IMG-007 is a humanized anti-OX40 monoclonal antibody designed to minimize safety risks and enable less frequent dosing regimens, with a half-life of 34.7 days [7]. - The drug has shown marked clinical activity and a well-tolerated safety profile in patients with moderate-to-severe atopic dermatitis during its Phase 2a trial [7]. Merger Details - The share issuance related to the merger is included in "PROPOSAL 1" of the proxy vote, alongside six additional proposals for the Annual Meeting [4]. - Stockholders as of May 22, 2025, are entitled to vote at the meeting, which will be held virtually [4]. Market Potential - The Ikena Board is optimistic about the merger with Inmagene, citing the potential of IMG-007 to create shareholder value in the immunological and inflammatory space [3].

Indonesian telecommunications tower company Dayamitra Telekomunikasi is considering reviving a merger with rival Tower Bersama Infrastructure, sources say https://t.co/ghZyBtPRvl ...